Search hospitals > British Columbia > VANCOUVER
G.I. Research Institute
Claim this profileVANCOUVER, British Columbia V6Z 2K5
Global Leader in Crohn's Disease
Global Leader in Inflammatory Bowel Disease
Conducts research for Ulcerative Colitis
Conducts research for Ulcer
Conducts research for Hepatitis
89 reported clinical trials
4 medical researchers
Summary
G.I. Research Institute is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis, Ulcer, Hepatitis and other specialties. G.I. Research Institute is involved with conducting 89 clinical trials across 56 conditions. There are 4 research doctors associated with this hospital, such as Gregory Rosenfeld, Hin Hin Ko, MD, Alnoor Ramji, MD, and Brian Bressler, MD.Top PIs
Gregory Rosenfeld(G.I.R.I.) GI Research Institute5 years of reported clinical research
Studies Crohn's Disease
Studies Ulcerative Colitis
7 reported clinical trials
5 drugs studied
Hin Hin Ko, MDSt. Paul's Hospital1 year of reported clinical research
Studies Liver Disease
Studies Autoimmune Hepatitis
3 reported clinical trials
3 drugs studied
Alnoor Ramji, MDPacific Gastroenterology Associates4 years of reported clinical research
Studies Varicose Veins
Studies Non-alcoholic Fatty Liver Disease
1 reported clinical trial
1 drug studied
Brian Bressler, MDGIRI (GI Research Institute)4 years of reported clinical research
Studies Ulcerative Colitis
Studies Ulcer
1 reported clinical trial
3 drugs studied
Clinical Trials running at G.I. Research Institute
Crohn's Disease
Ulcerative Colitis
Ulcer
Inflammatory Bowel Disease
Esophagitis
Eosinophilic Esophagitis
Celiac Disease
Liver Disease
Alcoholic Liver Disease
Cholangitis
Mirikizumab
for Crohn's Disease
This trial is testing mirikizumab to see if it can help people with Crohn's disease feel better over a long time and ensure it is safe. The drug works by reducing gut inflammation.
Recruiting2 awards Phase 3
TAK-279
for Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.t
Recruiting0 awards Phase 2
Combination Therapy
for Crohn's Disease
This trial is testing a new medication called JNJ-78934804 to see if it works better than two existing treatments for autoimmune conditions. The study will compare their effectiveness over several months.
Recruiting0 awards Phase 22 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at G.I. Research Institute?
G.I. Research Institute is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis, Ulcer, Hepatitis and other specialties. G.I. Research Institute is involved with conducting 89 clinical trials across 56 conditions. There are 4 research doctors associated with this hospital, such as Gregory Rosenfeld, Hin Hin Ko, MD, Alnoor Ramji, MD, and Brian Bressler, MD.